In-Person Versus Remote 6-Minute Walk and Incremental Shuttle Walk Distances in Advanced Lung Disease.

BACKGROUND: Field-based walk tests conducted remotely may provide an alternative method to a facility-based assessment of exercise capacity for people with advanced lung disease. This prospective study evaluated the level of agreement in the distance walked between a 6-min walk test (6MWT) and an incremental shuttle walk test performed by using standard in-person procedures and test variations and settings. METHODS: Adults with advanced lung disease underwent 4 study visits: (i) one in-person standard 6MWT (30-m corridor) and one in-person treadmill 6MWT, (ii) a remote 6MWT in a home setting (10-m corridor), (iii) 2 in-person standard incremental shuttle walk tests (10-m corridor), and (iv) a remote incremental shuttle walk test in a home setting (10-m corridor). A medical-grade oximeter measured heart rate and oxygen saturation before, during, and for 2 min after the tests. RESULTS: Twenty-eight participants were included (23 men [82%]; 64 (57-67) y old; 19 with interstitial lung disease [68%] and 9 with COPD [32%]; and 26 used supplemental oxygen (93%) [exertional [Formula: see text] of 0.46 ± 0.1]). There was no agreement between the tests. Greater walking distances were achieved with standard testing procedures: in-person 6MWT versus treadmill 6MWT (355 ± 68 vs 296 ± 97; P = .001; n = 28), in-person 6MWT versus remote 6MWT (349 ± 68 vs 293 ± 84; P = .001; n = 24), and in-person incremental shuttle walk test versus remote incremental shuttle walk test (216 ± 62 vs 195 ± 63; P = .03; n = 22). CONCLUSIONS: Differences in the distance walked may have resulted from different track lengths, widths, and walking surfaces. This should be considered in test interpretation if tests are repeated under different conditions.

The 6-min walk test: responses in healthy Canadians aged 45 to 85 years.

We sought to describe responses to the 6-min walk test (6MWT) in healthy Canadian adults in order to facilitate interpretation of its results in patient populations. Seventy-seven healthy Canadians aged 45 to 85 years (65 ± 11 years, 40 females) completed this study. During a single visit, three 6MWTs were undertaken. The main outcome measure was 6-min walk distance (6MWD). Age, gender, height, and weight were recorded. In 61 (79%) participants, cardiorespiratory variables were collected during the third 6MWT using a calibrated portable gas analysis system. The 6MWD increased between the first and second test (615 ± 96 to 639 ± 98 m; p < 0.001) with no further improvement on the third test (638 ± 99 m; p = 0.945). The best 6MWD from the first 2 tests was 640 ± 99 m (range 416 to 880 m). A greater 6MWD was achieved by males compared with females (672 ± 94 vs. 611 ± 93 m; p = 0.005). The following equation accounted for 49% of the variance in 6MWD: 6MWD = 970.7 + (-5.5 × age) + (56.3 × gender), where females = 0, males = 1. The 6MWT elicited large cardiorespiratory responses with minimal symptoms. The rate of oxygen uptake measured at test-end was associated with the 6MWD (r = 0.802; p < 0.001). These data allow the 6MWD achieved in Canadian adults to be expressed as a percentage of the predicted value and provide researchers and clinicians with values for the expected cardiorespiratory responses in a healthy adult population for the purpose of comparison with patient populations.